Glivec
imatinib
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Gastrointestinal Stromal Tumors
Dermatofibrosarcoma
Myelodysplastic-Myeloproliferative Diseases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hypereosinophilic Syndrome
Date of authorisation:
Revision: 48
Last updated:
MedicineHumanAuthorised
Imatinib Koanaa
imatinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic-Myeloproliferative Diseases
Hypereosinophilic Syndrome
Dermatofibrosarcoma
Gastrointestinal Stromal Tumors
Date of authorisation:
Last updated:
MedicineHumanWithdrawn
Imatinib Teva
imatinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic-Myeloproliferative Diseases
Hypereosinophilic Syndrome
Dermatofibrosarcoma
Date of authorisation:
Revision: 19
Last updated:
MedicineHumanAuthorised
Imatinib Accord
imatinib
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dermatofibrosarcoma
Myelodysplastic-Myeloproliferative Diseases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hypereosinophilic Syndrome
Date of authorisation:
Revision: 20
Last updated:
MedicineHumanAuthorised
Imatinib Actavis
imatinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic-Myeloproliferative Diseases
Hypereosinophilic Syndrome
Dermatofibrosarcoma
Date of authorisation:
Revision: 13
Last updated:
MedicineHumanWithdrawn
Imatinib medac
imatinib
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dermatofibrosarcoma
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myelodysplastic-Myeloproliferative Diseases
Hypereosinophilic Syndrome
Date of authorisation:
Revision: 5
Last updated:
MedicineHumanWithdrawn
EMEA-000463-PIP01-08-M03 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: P/0028/2012
Route(s) of administration: Oral use
Pharmaceutical form(s):
Capsule (hard)
Film-coated tablet
Decision date:
Last updated:
Compliance check: ✔
PIPHuman
EMEA-000463-PIP02-10 - paediatric investigation plan
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Cardiovascular diseases
PIP number: P/85/2011
Route(s) of administration: Oral use
Pharmaceutical form(s):
Film-coated tablet
Capsule (hard)
Age-appropriate oral solid dosage form
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
Bosatria
mepolizumab
Date of withdrawal:
Last updated:
MedicineHumanWithdrawn application